English
Home > Products > 3-Hydroxyazetidine Hydrochloride

China 3-Hydroxyazetidine Hydrochloride Factory

During the past few years, our business absorbed and digested state-of-the-art technologies the two at home and abroad. Meanwhile, our firm staffs a group of experts devoted to your development of 3-Hydroxyazetidine Hydrochloride,CAS NO 18621-18-6,18621-18-6,Baricitinib intermediate,Baricitinib advance intermediate, We've been devoted to offer professional purification technology and methods in your case!
3-Hydroxyazetidine Hydrochloride, Our Company policy is "quality first, to be better and stronger, sustainable development" . Our pursuit goals is "for society, customers, employees, partners and enterprises to seek reasonable benefit". We aspirate to do cooperate with all different the auto parts manufacturers, repair shop, auto peer , then create a beautiful future! Thank you for taking time to browse our website and we would welcome any suggestions you may have that can help us to improve our site.

Related Products

Hot Products

  • Roxadustat

    Roxadustat

    Product Name:Roxadustat
    Molecular Formula:C19H16N2O5
    Molecular Weight;352.34
    CAS Registry Number;808118-40-3
  • Trilostane

    Trilostane

    Product Name:Trilostane
    Molecular Formula:C20H27NO3
    Molecular Weight:329.43
    CAS Registry Number;13647-35-3
  • Dextranase

    Dextranase

    Product Name:Dextranase
    Molecular Formula:C6H12O7
    Molecular Weight:196.155
    CAS Registry Number:9025-70-1
  • Ropivacaine mesylate

    Ropivacaine mesylate

    Product Name:Ropivacaine mesylate
    Molecular Formula:C18H30N2O4S
    Molecular Weight;370.51
    CAS Registry Number;854056-07-8
  • Podophyllotoxin

    Podophyllotoxin

    Product Name:Podophyllotoxin
    Molecular Formula:C22H22O8
    Molecular Weight:414.41
    CAS Registry Number;518-28-5
  • Cis-hexahydroisoindoline HCL

    Cis-hexahydroisoindoline HCL

    Product Name:Cis-hexahydroisoindoline HCL
    Molecular Formula:C8H16ClN
    Molecular Weight:161.67234
    CAS Registry Number:161829-92-1
  • Related Blog
  • Reviews

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    Here are so many diseases that affect the human population in the current hours and so are the numerous drugs that are available to treat those diseases.

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept